Medical Editor: John P. Cunha, DO, FACOEP
Lotemax SM (loteprednol etabonate ophthalmic gel) is a corticosteroid indicated for the treatment of post-operative inflammation and pain following eye (ocular) surgery. Common side effects of Lotemax SM include:
- elevated eye (intraocular) pressure that may be associated with infrequent optic nerve damage,
- decreased sharpness of vision and reduced visual field,
- delayed wound healing,
- secondary eye infection, and
- perforation of the globe where there is thinning of the cornea or sclera
The dose of Lotemax SM is one drop applied into the conjunctival sac of the affected eye three times daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period. Lotemax SM may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Lotemax SM; it is unknown how it would affect a fetus. It is unknown if Lotemax SM passes into breast milk. Consult your doctor before breastfeeding.
Our Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, for Topical Ophthalmic Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle.
Read the entire FDA prescribing information for Lotemax SM (Loteprednol Etabonate Ophthalmic Gel)